Breaking News

Cellipont Bioservices, Mongoose Bio Partner to Advance MGB-001

Cellipont to provide technology transfer, process development, and cGMP manufacture of autologous MGB-001 TCR-T cell therapy program.

Cellipont Bioservices, a cell therapy CDMO, and Mongoose Bio, a clinical-stage biopharma company pioneering next gen precision T-cell based therapies targeting solid cancers, signed an agreement for the technology transfer, process development, and cGMP manufacture of its autologous MGB-001 TCR-T cell therapy program.
 
Mongoose Bio will leverage its antigen discovery pipeline and advanced memory T cell reprogramming technology to help address both common and rare solid tumors, delivering sustained immunoprotection. The platform integrates Generative Artificial Intelligence (Gen AI) to enhance the antigen discovery and T cell engineering processes, optimizing therapeutic efficacy and patient outcomes.
 
MGB-001, Mongoose Bio’s lead asset is an epigenetically reprogrammed autologous TCR-T cell therapy directed against a target that is both highly immunogenic and broadly expressed in many solid tumors. Unlike other TCRs on the market or in development, ID/validation of this TCR epitope was rigorously selected from among an unbiased pool of 1000s of well-curated MHC-eluted peptides, empirically validated, and clinically annotated to target pan-cancers. This therapy is built on 17 years of work by founder Dr. Cassian Yee at his lab at the University of Texas MD Anderson Cancer Center (MDACC). 
 
“We’re pleased to be partnering with Mongoose Bio on their MGB-001 TCR-T Cell Therapy program. “We look forward to collaborating and working with their team to deliver this novel cell therapy to cancer patients,” said Mike O’Mara, COO of Cellipont Bioservices.
 
“Cellipont is a strong partner for us and has excellent manufacturing capabilities to support advancing our lead candidate MGB-001 into the clinic,” said Neil Warma, President and CEO of Mongoose Bio.  “Our TCR-T therapies have the potential to transform the treatment of cancer and with Cellipont’s team of experts on board, we are on target to bring this very promising therapy to patients who have failed approved, front-line therapies in multiple tumor indications.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters